Year1
brr )
brr /, 黑体,r, ) r, usage and dosage
brr /, 黑体,r, ) Each tablet, one tablet a day, take on an empty stomach or with food
brr /, bold, r, ) can be combined with ribavirin or ribavirin + pegylated interferon to treat chronic hepatitis C (). The recommended combination treatment plan is as follows:
brr /, bold body, r, ) r, C alone infection
brr /, bold body, r, ) or/combined infection treatment plan treatment duration
brr /, boldface, r, ) genotype or type sofosbuvir+peginterferon&+ribavir
brr /, boldface,r, ) genotype sofosbuvir+ribavir Lin Zhou
brr /, boldface,r, ) Genotype sofosbuvir + ribavirin Zhou
brr /, boldface,r, ) Chronic hepatitis C patients who cannot use interferon may consider using it Sofosbuvir combined with ribavirin treatment weeks.
brr /, bold, r, ) Patients with hepatocellular carcinoma awaiting liver transplantation should be treated with sofosbuvir in combination with ribavirin for treatment of chronic hepatitis C for weeks or until liver transplantation, whichever occurs first.
brr /, bold, r, ) Dosing recommendations cannot be made for patients with severe renal impairment or end-stage renal disease.
brr /, boldface, r, ) r, dosage form
brr /, boldface, r, ) Each tablet: .
brr /, boldface,r, ) r , contraindications
brr /, boldface,r, ) &#Sofosbuvir combined with pegylated interferon&+ribavirin, or alone When used in combination with ribavirin, all contraindications for peginterferon and/or ribavirin also apply to combination therapy with sofosbuvir.
brr /, bold, r, ) &#Since ribavirin may cause fetal congenital malformation or stillbirth, [] therefore, sofosbuvir combined with pegylated interferon&+ribavirin, or Sofosbuvir alone in combination with ribavirin should be contraindicated in pregnant women and men whose partners are pregnant.
brr /, boldface, r, ) r, indications and uses
brr /, boldface, r, ) Sofosbuvir is a hepatitis C virus (C) nucleotide analog B Polymerase inhibitor, suitable for use as a combination component in a combined antiviral treatment regimen for the treatment of chronic hepatitis C (HCV) infection.
brr /, bold, r, ) Sofosbuvir has been proven effective in the treatment of genotyped or genotyped hepatitis C subjects, including hepatocellular carcinoma subjects who meet the Milan criteria and are waiting for liver transplantation, as well as C/complicated infections subjects.
brr /, bold, r, ) r, warnings and precautions
brr /, bold, r, ) Pregnancy: Ribavirin may cause fetal congenital malformations or stillbirth, and animal experiments have shown interference Elements can cause miscarriage. Therefore, female patients taking this drug and the spouses of male patients should avoid becoming pregnant. Before starting treatment, patients must have a negative pregnancy test, use at least two non-hormonal methods of contraception, and undergo monthly pregnancy tests.
brr /, boldface, r, ) r, adverse reactions
brr /, boldface, r, ) The most common known adverse reactions caused by sofosbuvir combined with ribavirin (the incidence rate is equal to or Greater than %, all grades) are headache and fatigue. The most common known adverse reactions caused by sofosbuvir in combination with peginterferon and ribavirin include fatigue, headache, nausea, insomnia, and anemia.
brr /, boldface, r, ) r , drug interactions
brr /, boldface,r, ) Potent intestinal glycoprotein (r) inducers (such as rifampicin) may alter sofe Buvet drug plasma concentrations. Before use, please read the complete package insert for drug-drug interactions.
brr /, boldface, r, ) r, medication for special groups
brr /, boldface, r, ) C/Patients with co-infections: The safety and effectiveness of this drug have been confirmed by research.
brr /, bold, r, ) Hepatocellular carcinoma patients awaiting liver transplantation: The safety and effectiveness of this drug have been confirmed by studies.
brr )
WhatsApp
